QCI Interpret for Oncology

Gaining insights with transcriptomic profiling and mechanistic modeling

June 11, 2021
In this webinar, Moritz Schütte, head of next-generation sequencing data analysis at Alacris, will explore the advantages of RNA sequencing alone or in combination with whole-exome sequencing as part of a precision oncology workflow.

In addition to discussing how RNA-seq identifies molecular alterations and illuminates the tumor microenvironment, Dr. Schütte will explain how mathematical modeling of molecular data can predict drug sensitivity. Applications will be shown for metastatic melanoma and acute lymphoblastic leukemia.

In this webinar, you will learn:

How comprehensive analysis is able to detect actionable targets not accessible by panel analysis;
How deep transcriptome profiling gives insights into the tumor microenvironment and immune composition;
How transcriptome sequencing can be applied for molecular profiling of acute lymphoblastic leukemias in relapse;
How mechanistic modeling offers a highly complementary information layer and enables in silico testing of drug response.

Related videos

QCI Interpret for Oncology

Going beyond: Molecular evidence for off-label therapy use

149 views June 02, 2021

Kathryn Bungartz, Ph.D., Associate StaffField Application Scientist, QIAGEN...

QCI Interpret for Oncology

Confidence and trust: Deliver valuable clinical insights with high-quality knowledge

211 views June 02, 2021

Ben Turner, Director of Bioinformatics Enterprise Solutions, QIAGEN Digital...

QCI Interpret for Oncology

Generate oncologist-ready clinical reports from comprehensive panels

218 views June 02, 2021

Ruth Burton, Ph.D., Clinical Application Specialist, QIAGEN Digital Insights...

QCI Interpret for Oncology

QCI Interpret One: Oncology variant interpretation just got more precise

939 views June 12, 2020

Competing to offer a comprehensive genomic profiling service for solid or...